Cue Biopharma (CUE) Operating Expenses (2017 - 2025)

Cue Biopharma has disclosed Operating Expenses across 9 years of filings, most recently posting $20.0 million for Q4 2025.

• Operating Expenses for Q4 2025 came in at $20.0 million, up 78.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $54.0 million (up 6.36% YoY), and the FY2025 annual result was $54.0 million, up 6.36% from the prior year.
• Operating Expenses came in at $20.0 million for Q4 2025 at Cue Biopharma, up from $9.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $20.0 million in Q4 2025 to a low of $9.7 million in Q3 2025.
• The 5-year median for Operating Expenses is $13.5 million (2023), against an average of $13.8 million.
• Across the five-year window, Operating Expenses retreated 28.39% in 2024 and jumped 78.11% in 2025, its largest moves.
• Cue Biopharma's Operating Expenses stood at $16.1 million in 2021, then retreated by 7.0% to $15.0 million in 2022, then increased by 4.24% to $15.7 million in 2023, then declined by 28.39% to $11.2 million in 2024, then surged by 78.11% to $20.0 million in 2025.
• The last three Operating Expenses figures came in at $20.0 million (Q4 2025), $9.7 million (Q3 2025), and $11.6 million (Q2 2025), per Business Quant data.